Lisata Therapeutics
LSTA
29 hedge funds and large institutions have $4.49M invested in Lisata Therapeutics in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
6% more capital invested
Capital invested by funds: $4.25M → $4.49M (+$247K)
4% more funds holding
Funds holding: 28 → 29 (+1)
0.06% more ownership
Funds ownership: 0.46% → 0.52% (+0.06%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $77K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$461K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$266K |
| 3 |
TFO
Tarbox Family Office
Newport Beach,
California
|
+$63K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.2K |
| 5 |
Morgan Stanley
New York
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$226K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$65.3K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$6.39K |
| 5 |
Barclays
London,
United Kingdom
|
-$3.28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Barclays
London,
United Kingdom
| – | -$3.28K | -40 | -91% |
|
27
UBS Group
Zurich,
Switzerland
| – | -$2.95K | -36 | -97% |
|
|
SWP
28
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$82 | +1 | New |
|
LSTA Hedge Fund Activity: Q3 2018 in Review
29 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2018, worth a combined $4.49M — up 5.8% from $4.25M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LSTA positions and 1 closed out — a net gain of 1 holder — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $461K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $226K sold.
- 29 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2018, up from 28 in Q2 2018.
- Funds reported $4.49M of Lisata Therapeutics stock for Q3 2018, up 5.8% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q3 2018 and 1 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $461K added.
- The largest Lisata Therapeutics seller in Q3 2018 was Jacobs Levy Equity Management, an estimated $226K sold.
Based on aggregated 13F filings for Q3 2018.